Silo Pharma and Strategic Partner Zylo Therapeutics Begin Development Process for Novel Ketamine Loaded Z-Pods
November 18, 2021 09:45 ET
|
Silo Pharma, Inc.
Englewood Cliffs NJ, Nov. 18, 2021 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (OTCQB: SILO) a development-stage biopharmaceutical company focused on the use of psychedelics as a therapeutic, today...
Silo Pharma Reports Third Quarter Results and Operating Highlights
November 11, 2021 08:09 ET
|
Silo Pharma, Inc.
Englewood Cliffs, NJ, Nov. 11, 2021 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (OTCQB: SILO), a development-stage biopharmaceutical company focused on the use of psychedelics as a therapeutic, today...
Silo Pharma Enters into Sponsored Research Agreement with Columbia University to Develop Psychedelic Therapeutics for Alzheimer’s Disease
October 27, 2021 08:11 ET
|
Silo Pharma, Inc.
Englewood Cliffs NJ, Oct. 27, 2021 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (OTCQB: SILO), a development-stage biopharmaceutical company focused on the use of psychedelics as a therapeutic, today...
Silo Pharma achieves milestone - Partner Zylo Therapeutics Receive DEA Approval to Advance Silos time released Ketamine technology
October 07, 2021 08:11 ET
|
Silo Pharma, Inc.
Englewood Cliffs NJ, Oct. 07, 2021 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (OTCQB: SILO) a development-stage biopharmaceutical company focused on the use of psychedelics as a therapeutic, today...
Silo Pharma Advances Psychedelic Patent Portfolio
August 25, 2021 08:01 ET
|
Silo Pharma, Inc.
Englewood Cliffs NJ, Aug. 25, 2021 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (OTCQB: SILO), a development-stage biopharmaceutical company focused on the use of psychedelics as a therapeutic, today...
Silo Pharma Announces that JV partner Zylo Therapeutics Successfully Completes Initial Inspection for Ketamine Intradermal Research
August 11, 2021 08:10 ET
|
Silo Pharma, Inc.
Englewood Cliffs NJ, Aug. 11, 2021 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (OTCQB:SILO), a development-stage biopharmaceutical company focused on the use of psychedelics as a therapeutic, today...
Silo Pharma Awarded Notice of Allowance from United States Patent and Trademark Office for Homing Peptide Patent
July 27, 2021 08:08 ET
|
Silo Pharma, Inc.
Central Nervous System Homing Peptide under development to deliver Psychedelics including Psilocybin Englewood Cliffs NJ, July 27, 2021 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (OTCQB:SILO), a...
Silo Pharma To Appear On National Media Broadcast on Psychedelics
July 21, 2021 10:42 ET
|
Silo Pharma, Inc.
Englewood Cliffs, NJ , July 21, 2021 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (OTCQB: SILO), a development-stage biopharmaceutical company focused on the use of psychedelics as a therapeutic, has...
Silo Pharma Enters into Sponsored Research Agreement with the University of Maryland, Baltimore
July 12, 2021 08:08 ET
|
Silo Pharma, Inc.
Englewood Cliffs NJ, July 12, 2021 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (OTCQB: SILO), a development stage biopharmaceutical company, today announced that it has entered into a Scientific Research...
Silo Pharma extends agreement for experimental Rheumatoid Arthritis nanoparticle homing peptide
July 07, 2021 08:15 ET
|
Silo Pharma, Inc.
Englewood Cliffs NJ, July 07, 2021 (GLOBE NEWSWIRE) -- Silo and University of Maryland, Baltimore extend Option agreement Rheumatoid arthritis (RA) is a chronic disease in which autoimmune attack...